These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

795 related items for PubMed ID: 29609120

  • 1. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li N, Wang LJ, Jiang B, Li XQ, Guo CL, Guo SJ, Shi DY.
    Eur J Med Chem; 2018 May 10; 151():145-157. PubMed ID: 29609120
    [Abstract] [Full Text] [Related]

  • 2. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.
    Meduru H, Wang YT, Tsai JJ, Chen YC.
    Int J Mol Sci; 2016 Jun 13; 17(6):. PubMed ID: 27304951
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Novel DPP-4 inhibitors against diabetes.
    Liu Y, Hu Y.
    Future Med Chem; 2014 May 13; 6(7):793-808. PubMed ID: 24941873
    [Abstract] [Full Text] [Related]

  • 7. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Yoshida T, Akahoshi F, Sakashita H, Kitajima H, Nakamura M, Sonda S, Takeuchi M, Tanaka Y, Ueda N, Sekiguchi S, Ishige T, Shima K, Nabeno M, Abe Y, Anabuki J, Soejima A, Yoshida K, Takashina Y, Ishii S, Kiuchi S, Fukuda S, Tsutsumiuchi R, Kosaka K, Murozono T, Nakamaru Y, Utsumi H, Masutomi N, Kishida H, Miyaguchi I, Hayashi Y.
    Bioorg Med Chem; 2012 Oct 01; 20(19):5705-19. PubMed ID: 22959556
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors.
    Li N, Wang LJ, Jiang B, Guo SJ, Li XQ, Chen XC, Luo J, Li C, Wang Y, Shi DY.
    Bioorg Med Chem Lett; 2018 Jul 01; 28(12):2131-2135. PubMed ID: 29773502
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
    Wang J, Feng Y, Ji X, Deng G, Leng Y, Liu H.
    Bioorg Med Chem; 2013 Dec 01; 21(23):7418-29. PubMed ID: 24153396
    [Abstract] [Full Text] [Related]

  • 11. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
    Maezaki H, Banno Y, Miyamoto Y, Moritoh Y, Asakawa T, Kataoka O, Takeuchi K, Suzuki N, Ikedo K, Kosaka T, Sasaki M, Tsubotani S, Tani A, Funami M, Yamamoto Y, Tawada M, Aertgeerts K, Yano J, Oi S.
    Bioorg Med Chem; 2011 Aug 01; 19(15):4482-98. PubMed ID: 21741847
    [Abstract] [Full Text] [Related]

  • 12. Integrated Protocol to Design Potential Inhibitors of Dipeptidyl Peptidase- 4 (DPP-4).
    Pantaleão SQ, Philot EA, de Oliveira Almeida M, Lima AN, de Sairre MI, Scott AL, Honorio KM.
    Curr Top Med Chem; 2020 Aug 01; 20(3):209-226. PubMed ID: 31878857
    [Abstract] [Full Text] [Related]

  • 13. Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors.
    Li Q, Zhou M, Han L, Cao Q, Wang X, Zhao L, Zhou J, Zhang H.
    Chem Biol Drug Des; 2015 Oct 01; 86(4):849-56. PubMed ID: 25787859
    [Abstract] [Full Text] [Related]

  • 14. An Update on Dipeptidyl Peptidase-IV Inhibiting Peptides.
    Sivaraman SA, Sabareesh V.
    Curr Protein Pept Sci; 2024 Oct 01; 25(4):267-285. PubMed ID: 38173201
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.
    Kushwaha RN, Srivastava R, Mishra A, Rawat AK, Srivastava AK, Haq W, Katti SB.
    Chem Biol Drug Des; 2015 Apr 01; 85(4):439-46. PubMed ID: 25216392
    [Abstract] [Full Text] [Related]

  • 16. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
    Juillerat-Jeanneret L.
    J Med Chem; 2014 Mar 27; 57(6):2197-212. PubMed ID: 24099035
    [Abstract] [Full Text] [Related]

  • 17. An overview of recent dipeptidyl peptidase-IV inhibitors: linking their structure and physico-chemical properties with sar, pharmacokinetics and toxicity.
    Smelcerovic A, Miljkovic F, Kolarevic A, Lazarevic J, Djordjevic A, Kocic G, Anderluh M.
    Curr Top Med Chem; 2015 Mar 27; 15(23):2342-72. PubMed ID: 26088350
    [Abstract] [Full Text] [Related]

  • 18. Structure-based virtual screening of dipeptidyl peptidase 4 inhibitors and their in vitro analysis.
    Rahman SU, Ali HS, Jafari B, Zaib S, Hameed A, Al-Kahraman YMSA, Langer P, Iqbal J.
    Comput Biol Chem; 2021 Apr 27; 91():107326. PubMed ID: 32739275
    [Abstract] [Full Text] [Related]

  • 19. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors.
    Deng X, Han L, Zhou J, Zhang H, Li Q.
    Bioorg Chem; 2017 Dec 27; 75():357-367. PubMed ID: 29096096
    [Abstract] [Full Text] [Related]

  • 20. Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer.
    De S, Banerjee S, Kumar SKA, Paira P.
    Mini Rev Med Chem; 2019 Dec 27; 19(2):88-97. PubMed ID: 29692250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.